ARTICLE | Clinical News
PA21 regulatory update
February 18, 2013 8:00 AM UTC
Galenica's specialty pharma business Vifor Pharma Ltd. submitted an NDA to FDA for PA21 to treat hyperphosphatemia in patients with chronic kidney disease (CKD). Separately, EMA accepted for review an...